[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369986-105":59,"doc-detail-369986-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","screening-of-the-founder-pathogenic-variants-brca1-and-brca2-in-russian-metropolitan-women","Screening of the founder pathogenic variants BRCA1 and BRCA2 in Russian metropolitan women","","Hereditary cancer driven by high-risk BRCA1 and BRCA2 pathogenic variants accounts for 5–10% of breast cancer cases and creates a substantial burden on healthcare systems. Harm can be reduced through timely genetic detection and structured monitoring of variant carriers. A population-based genetic screening in a large metropolitan area in 2018 tested eight recurrent founder variants using validated real-time PCR. Women with detected variants entered a prospective surveillance program. The study reports prevalence, genotype distribution, uptake, cancer incidence and stage, and evaluates adherence to screening guidelines, emphasizing improved protocols and follow-up for earlier cancer detection.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/screening-of-the-founder-pathogenic-variants-brca1-and-brca2-in-russian-metropolitan-women/369986/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/screening-of-the-founder-pathogenic-variants-brca1-and-brca2-in-russian-metropolitan-women/369986.png","ImageObject",300,407,{"name":92,"@type":93},"PakDamar76","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-16","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What problem does the study address regarding BRCA1/BRCA2 variants?","Question",{"text":113,"@type":114},"Hereditary cancer risks linked to BRCA1/BRCA2 pathogenic variants are responsible for a meaningful share of breast cancer cases. The study focuses on reducing harm via early detection and monitoring of carriers.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were women selected and what testing strategy was used?",{"text":118,"@type":114},"The study conducted population-based genetic screening of unselected women in a large metropolitan area in 2018. It tested eight recurrent BRCA1/2 founder pathogenic variants using validated real-time PCR assays.",{"name":120,"@type":111,"acceptedAnswer":121},"What were the main findings on variant prevalence and cancer detection timing?",{"text":122,"@type":114},"Among 107,300 women, 402 carried BRCA1/2 founder pathogenic variants (386 BRCA1, 16 BRCA2). Early-stage cancer detection among carriers increased from 65% to 93% through follow-up surveillance, and variant carriers showed significantly higher cancer incidence than relatives without variants.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},369986,1790463131,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962090893057,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Bodunova etal. BMC Women's Health (2025) 25:601 BMC Women's Health  \n[https://doi.org/10.1186/s12905-025-04164-6](https://doi.org/10.1186/s12905-025-04164-6)  \nRESEARCH Open Access  \nScreening of the founder pathogenic variants BRCA1 and BRCA2 in Russian metropolitan women  \nNatalia Bodunova 1, Airat Bilyalov 1,2, Anastasiia Danishevich 1, Gurami Kvetenadze 1, Artem Andronov 1, Andrey Starshinin3, Konstantin Rumyantsev 1*, Ludmila Zhukova 1, Alexey Khripun3 and Igor Khatkov 1  \nAbstract  \nBackground Hereditary cancer and associated high risk genetic variants accountable for 5–10% of all breast cancer cases carry a significant burden on the health system and the pathogenic variants carriers. The harm from these factors can be significantly reduced through the timely detection of genetic alterations and implementation of health monitoring programs for pathogenic variants carriers.  \nMethods We conducted a population-based genetic screening of unselected women residing in a large metropolitan area in 2018. Testing targeted eight recurrent BRCA1/2 founder pathogenic variants using validated realtime PCR assays. Women with a detected variant were invited into a structured prospective surveillance program with standardized capture of clinical outcomes. The primary outcome was the prevalence of BRCA1/2 founder variants; secondary outcomes included age and family-history profiles, adherence to surveillance, and cancer incidence and stage among carriers. Analyses used descriptive summaries, χ² or Fisher’s exact tests for proportions, Mann–Whitney tests for continuous variables, and risk ratios with 95% confidence intervals.  \nResults The study included a large cohort of 107,300 women. 402 identified pathogenic variant carriers were offered consultations by a geneticist and regular health monitoring, 94. 3% of them agreed to participate and made a median of two visits. Among 402 identified BRCA1/2 pathogenic variant carriers, 386 women (0 . 36%) had pathogenic variants in the BRCA1 gene and 16 women (0 . 01%) had pathogenic variants in the BRCA2 gene. The BRCA1 variant c. 5266dup accounted for 66. 2% of all pathogenic variant detected. BRCA1/2 pathogenic variants were significantly associated with a high incidence of cancer in both pathogenic variants carriers and their relatives. Only 27. 2% of pathogenic variants carriers met clinical guidelines for genetic screening, while 6. 3% of women without detected pathogenic variants were eligible for genetic testing. Through a follow-up medical surveillance program, the percentage of cancers detected at an early stage in pathogenic variants carriers increased from 65% to 93% .  \nConclusions The findings ofthis study highlight the critical need for improved genetic screening protocols to identify high-risk individuals effectively. By refining clinical guidelines and implementing comprehensive follow-up  \n*Correspondence:  \nKonstantin Rumyantsev [konstantinrumyantsev88@yahoo.com](konstantinrumyantsev88@yahoo.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission direc","cbCaicaIwIPX1qvf","https://ap.wps.com/l/cbCaicaIwIPX1qvf","pdf",1776939,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Keywords\n# Background\n## Hereditary cancer risk and molecular diagnostics\n## Founder variant panels for Russia","[{\"question\":\"What problem does the study address regarding BRCA1/BRCA2 variants?\",\"answer\":\"Hereditary cancer risks linked to BRCA1/BRCA2 pathogenic variants are responsible for a meaningful share of breast cancer cases. The study focuses on reducing harm via early detection and monitoring of carriers.\"},{\"question\":\"How were women selected and what testing strategy was used?\",\"answer\":\"The study conducted population-based genetic screening of unselected women in a large metropolitan area in 2018. It tested eight recurrent BRCA1/2 founder pathogenic variants using validated real-time PCR assays.\"},{\"question\":\"What were the main findings on variant prevalence and cancer detection timing?\",\"answer\":\"Among 107,300 women, 402 carried BRCA1/2 founder pathogenic variants (386 BRCA1, 16 BRCA2). Early-stage cancer detection among carriers increased from 65% to 93% through follow-up surveillance, and variant carriers showed significantly higher cancer incidence than relatives without variants.\"}]","Screening of the founder pathogenic variants BRCA1 and BRCA2 in Russian metropolitan women | PDF",1790186160,25,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/01fb4a8a0d701bd834ad6368b8e48834.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3b11a442907b0e0cb4b75d6b22d67de7.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fd1c0dbb9c0c23d1c8ede4d383ba7b33.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f9e54e118ed9fc1240c1d2da0fb73767.webp",980,1306]